Site icon The Word 360

DeSci (Decentralized Science): How Web3 Is Changing Biotech Research

DeSci (Decentralized Science): How Web3 Is Changing Biotech Research

DeSci (Decentralized Science): How Web3 Is Changing Biotech Research

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"173035871"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p dir&equals;"ltr">Decentralized science&comma; or DeSci&comma; uses blockchain tools such as DAOs&comma; tokens&comma; and IP-NFTs to fund and share scientific research outside traditional grants and journals&period; In biotech&comma; the best-known example is VitaDAO&comma; a community-funded longevity group that Pfizer Ventures invested in&period; The movement is real but small&period; Two secondary sources count about 50 active projects and more than &dollar;60 million in cumulative funding&comma; while the US National Institutes of Health received about &dollar;47 billion in base funding for fiscal year 2026&period; This guide explains how DeSci works&comma; who the main players are&comma; and where the evidence is weak&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">What DeSci Tries to Fix<&sol;h2>&NewLine;<p dir&equals;"ltr">Supporters point to slow grant cycles&comma; paywalled journals&comma; and research that never gets commercialized&period; A California Management Review article &lpar;November 2025&rpar; frames DeSci as a possible next frontier of scientific research&comma; while also listing risks&colon; regulation of crypto is &&num;8220&semi;in flux&comma;&&num;8221&semi; and there are data privacy conflicts&comma; scalability problems&comma; and concentrated governance&period; The case for DeSci is that a global community can fund early-stage ideas that traditional funders skip&period; The case against is that token markets may reward hype over science&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">How It Works&colon; DAOs&comma; Tokens&comma; and IP-NFTs<&sol;h2>&NewLine;<p dir&equals;"ltr">A DAO&comma; or decentralized autonomous organization&comma; is a group that pools money and votes on how to spend it&comma; using tokens as membership&period; An IP-NFT&comma; as used by the biotech platform Molecule&comma; is a token that represents rights to research intellectual property&comma; so a community can co-own a project&&num;8217&semi;s potential outcomes&period; Molecule&&num;8217&semi;s 2025 recap says it has since built a new legal framework that places IP-NFTs inside corporations with equity for qualified contributors&comma; which it calls &&num;8220&semi;IP RWAs&&num;8221&semi; &lpar;real-world assets&rpar;&comma; and that it is integrating with BIO Protocol and pump&period;science&period; A brand refresh was planned for the first quarter of 2026&period; The recap gives no numbers&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">VitaDAO&colon; The Flagship<&sol;h2>&NewLine;<p dir&equals;"ltr">The Block reported in October 2023 that VitaDAO&comma; launched in 2021 as a longevity DAO&comma; had over 10&comma;000 members&comma; 19 funded projects&comma; and about &dollar;4 million deployed&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr"><strong>The Pfizer Connection<&sol;strong><&sol;h3>&NewLine;<p dir&equals;"ltr">Pfizer Ventures committed &dollar;500&comma;000 in September 2022 and joined a &dollar;4&period;1 million token round in January 2023 alongside Shine Capital&comma; L1 Digital&comma; and Balaji Srinivasan&comma; according to The Block&period; It was Pfizer&&num;8217&semi;s first DAO investment&comma; held through a special purpose vehicle&period; VitaDAO&&num;8217&semi;s first spinout biotech&comma; Matrix Biosciences&comma; received &dollar;300&comma;000 from VitaDAO and works with Dr&period; Vera Gorbunova of the University of Rochester on compounds based on naked mole rat hyaluronic acid&period; Note the distinction&colon; Matrix is a VitaDAO company&comma; and Pfizer is a VitaDAO investor&comma; not a partner of Matrix&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr"><strong>Funding Claims Differ<&sol;strong><&sol;h3>&NewLine;<p dir&equals;"ltr">Sources disagree on how much VitaDAO raised&period; The Block cites a &dollar;4&period;1 million round&comma; a KuCoin blog says historical raises are about &dollar;4&period;6 million&comma; and the California Management Review says &&num;8220&semi;over &dollar;10m through a token sale&period;&&num;8221&semi; That article lists funded examples&comma; including BE Therapeutics at &dollar;100&comma;000&comma; the Korolchuk Lab at &dollar;285&comma;000&comma; and Matrix Bio at &dollar;300&comma;000&period; These numbers cannot all be reconciled with the sources available&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">BIO Protocol and the BioDAO Wave<&sol;h2>&NewLine;<p dir&equals;"ltr">Cointelegraph reported on November 8&comma; 2024 that Binance Labs made its first DeSci investment in BIO Protocol&comma; with the amount undisclosed&period; KuCoin Research&&num;8217&semi;s report says BIO raised over &dollar;33 million during its Genesis phase in November 2024&comma; with a 3&period;32 billion total supply&comma; 20 percent allocated to the Genesis auction&comma; and 5 percent &lpar;166 million tokens&comma; vesting over four years&rpar; going to Molecule for transferring its core IP and brand to the Bio&period;xyz Association&period; It lists BioDAOs including VitaDAO&comma; AthenaDAO&comma; PsyDAO&comma; and ValleyDAO&comma; and an airdrop covering over 8&comma;500 addresses&period; Those sources are an exchange&&num;8217&semi;s own research pages&comma; so treat the figures cautiously&period; A claim of a Binance spot listing in 2025 could not be verified&comma; and this article gives no token prices&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Other Projects<&sol;h2>&NewLine;<p dir&equals;"ltr">ResearchHub&comma; co-founded by Coinbase CEO Brian Armstrong and Patrick Joyce&comma; announced a &dollar;5 million seed on June 15&comma; 2023&comma; led by Open Source Software Capital&comma; with angels including Guillermo Rauch&comma; Amjad Masad&comma; and Garry Tan&period; The Block reported that it pays a token&comma; ResearchCoin&comma; for publishing and peer review&period; This research found no results data for ResearchHub&period;<&sol;p>&NewLine;<p dir&equals;"ltr">A KuCoin blog from May 1&comma; 2026&comma; which appears machine-translated marketing&comma; claims NanoVita closed a Series A in early April 2026 at a &dollar;20 million post-money valuation&comma; and that Sei Foundation&&num;8217&semi;s Sapien Capital fund is &dollar;65 million&period; Given its source&comma; take these as unconfirmed&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">How Big Is DeSci&comma; Really&quest;<&sol;h2>&NewLine;<p dir&equals;"ltr">The California Management Review cites over 50 active DeSci projects &lpar;December 2024&comma; citing DWF Labs&rpar; and more than &dollar;60 million in combined funding&comma; but also a RootData figure of two public funding rounds totaling &dollar;11&period;2 million in one year&period; The KuCoin blog repeats about 50 projects and over &dollar;60 million&period; Against that&comma; the American Association for Cancer Research reported that Congress provided &dollar;47&period;2 billion in base NIH funding for fiscal 2026&comma; with a cited total of &dollar;48&period;7 billion&comma; rejecting proposed deep cuts&comma; while the fiscal 2027 request is about &dollar;41&period;1 billion&period; By my own arithmetic&comma; &dollar;60 million is roughly 0&period;13 percent of one year of NIH base funding&period; DeSci is a rounding error next to public science funding&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">What Has Not Been Shown<&sol;h2>&NewLine;<p dir&equals;"ltr">This research found no verified SEC action against a DeSci project&comma; no shutdown of a major project&comma; and no commentary from Nature or Science&period; It also found no independently reported scientific result funded by a DeSci group&period; Absence of evidence is not proof of success or failure&comma; but readers should ask which discoveries&comma; if any&comma; these communities have enabled&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Risks to Weigh<&sol;h2>&NewLine;<p dir&equals;"ltr">Token prices can swing and may attract speculation instead of scientific interest&period; Governance can concentrate power in large token holders&period; Patient or research data on public chains raises privacy questions&period; Regulation is uncertain&period; Funding totals are hard to verify&period; None of this is investment advice&comma; and this article makes no recommendation to buy any token&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Why It Still Matters<&sol;h2>&NewLine;<p dir&equals;"ltr">Even skeptics can see the appeal of open funding for neglected ideas&comma; faster sharing of results&comma; and rewards for peer review&period; If a DeSci project produces a drug candidate that passes real trials&comma; the model would gain credibility&period; Until then&comma; the honest description is an experiment&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">How to Evaluate a DeSci Project<&sol;h2>&NewLine;<p dir&equals;"ltr">Look for named scientists and institutions&period; Check who owns the intellectual property and how decisions are made&period; Read the legal structure behind any token&period; Look for peer-reviewed or independently verified results&period; Be careful with exchange-published research and promotional posts&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Questions a Critical Reader Should Ask<&sol;h2>&NewLine;<p dir&equals;"ltr">Who are the scientists behind the project&comma; and are they affiliated with recognized institutions&quest; The Matrix Bio example names Dr&period; Vera Gorbunova of the University of Rochester&comma; which is the kind of detail to look for&period; What exactly does the token give holders&colon; voting rights&comma; IP rights&comma; or only speculation&quest; Where does the money go&comma; and how much reaches laboratory work&quest; Has any project published results&comma; entered trials&comma; or produced a licensable asset&quest; The research for this article found no verified results of this kind&comma; which is the central gap in the story&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">DeSci and Conventional Funders Together<&sol;h2>&NewLine;<p dir&equals;"ltr">DeSci does not have to replace traditional funding to be useful&period; Pfizer Ventures&&num;8217&semi; investment in VitaDAO shows a conventional pharmaceutical investor experimenting with the model&period; The Berkeley article frames DeSci as a possible complement for early-stage work&period; For now&comma; the more realistic role is as a small funder of experimental or neglected ideas next to large public funders&comma; not a substitute for them&period; If a few projects deliver clear results&comma; the model could grow&period; If not&comma; it may remain a niche&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">A Brief Glossary<&sol;h2>&NewLine;<p dir&equals;"ltr">A DAO is an online organization governed by token holders who vote on proposals&period; A BioDAO is a DAO focused on a biotech or health topic&comma; such as VitaDAO for longevity&comma; AthenaDAO&comma; PsyDAO&comma; and ValleyDAO&comma; as listed in the KuCoin report&period; An IP-NFT is a token tied to rights in research intellectual property&period; A spinout is a company created from a funded project&comma; like Matrix Bio&period; A launchpad is a platform that helps projects issue tokens&comma; which is how the sources describe BIO Protocol&period; A special purpose vehicle is a legal entity formed for a specific investment&comma; as Pfizer Ventures used for its VitaDAO holding&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">How Traditional Funding Compares<&sol;h2>&NewLine;<p dir&equals;"ltr">Traditional science funding runs through government agencies&comma; universities&comma; foundations&comma; and companies&comma; with peer review and long timelines&period; The NIH figures show the scale&colon; &dollar;47&period;2 billion in base funding for fiscal 2026 according to AACR&comma; with Congress rejecting proposed deep cuts and the next request at about &dollar;41&period;1 billion&period; Those numbers also show how exposed science is to political decisions&comma; which supporters of DeSci cite as a reason for alternatives&period; Critics respond that tokens introduce a different exposure&comma; to markets&period; Neither side has proven its case&comma; and the available evidence is limited&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">What Would Make DeSci Credible<&sol;h2>&NewLine;<p dir&equals;"ltr">Three things would help&colon; independent verification of funding totals&comma; published results from funded projects&comma; and clarity on legal structures&period; The Molecule recap&&num;8217&semi;s move toward corporate equity structures suggests the field is already adjusting to legal realities&period; If a funded project reports clinical or laboratory milestones that others can check&comma; skeptics will have a reason to pay attention&period; Until then&comma; treat claims with the same scrutiny you would give any early-stage research&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Who This Matters To<&sol;h2>&NewLine;<p dir&equals;"ltr">Researchers might use DeSci as an additional funding route for ideas that struggle to win grants&period; Investors might see it as speculative exposure&comma; with the risks above&period; Patients and advocacy groups might see community funding for neglected conditions&period; Journalists and policy makers might watch for regulatory moves&comma; although no SEC action was verified for this article&period; Each audience should read the sources&comma; not the marketing&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">What the Numbers Do and Do Not Show<&sol;h2>&NewLine;<p dir&equals;"ltr">The funding figures in this article illustrate the problem of verification&period; A cumulative figure of &dollar;60 million&comma; a one-year figure of &dollar;11&period;2 million&comma; a &dollar;4&period;1 million round&comma; and a &dollar;33 million token event all appear in sources of different quality&comma; and some come from exchanges with a commercial interest in token activity&period; As of November 9&comma; 2026&comma; a fresh search found no newly verified funded result&comma; regulatory action or major journal commentary&comma; and the funding figures remain the same&period; The most credible numbers here come from The Block&&num;8217&semi;s reporting on identifiable rounds and from AACR&&num;8217&semi;s summary of NIH appropriations&period; Treat the rest as claims&period; This is a normal feature of a young sector&comma; and it is why this article keeps the language cautious&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Where the Pfizer Story Fits<&sol;h2>&NewLine;<p dir&equals;"ltr">Headlines that link Pfizer to decentralized science can mislead if read quickly&period; The Block&&num;8217&semi;s report says Pfizer Ventures invested in VitaDAO&&num;8217&semi;s token round through a special purpose vehicle&period; It does not say Pfizer is partnering on drug development with Matrix Bio or any other DAO project&period; The investment was described as Pfizer&&num;8217&semi;s first DAO investment&comma; which is a notable signal of interest&comma; not evidence of scientific validation&period; Reading carefully matters in this sector&comma; where promotional language is common&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr">Frequently Asked Questions<&sol;h2>&NewLine;<h3 dir&equals;"ltr">What is DeSci&quest;<&sol;h3>&NewLine;<p dir&equals;"ltr">Decentralized science&comma; which uses blockchain tools such as DAOs and tokens to fund and share research&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr">Did Pfizer invest in DeSci&quest;<&sol;h3>&NewLine;<p dir&equals;"ltr">Pfizer Ventures invested in VitaDAO&comma; committing &dollar;500&comma;000 in September 2022 and joining a &dollar;4&period;1 million round in January 2023&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr">How big is DeSci funding&quest;<&sol;h3>&NewLine;<p dir&equals;"ltr">Secondary sources cite about 50 projects and over &dollar;60 million&comma; though another figure says &dollar;11&period;2 million in two rounds in a year&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr">What is an IP-NFT&quest;<&sol;h3>&NewLine;<p dir&equals;"ltr">A token representing rights to research intellectual property&comma; used by Molecule&period;<&sol;p>&NewLine;<h3 dir&equals;"ltr">Is DeSci a replacement for the NIH&quest;<&sol;h3>&NewLine;<p dir&equals;"ltr">No&period; NIH base funding for fiscal 2026 was &dollar;47&period;2 billion&period;<&sol;p>&NewLine;<h2 dir&equals;"ltr"><strong>References and Sources<&sol;strong><&sol;h2>&NewLine;<p dir&equals;"ltr">The Block&comma; &&num;8220&semi;Pfizer-backed DAO launches community-funded biotech firm&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;www&period;theblock&period;co&sol;post&sol;255164&sol;pfizer-backed-dao-launches-community-funded-biotech-firm">https&colon;&sol;&sol;www&period;theblock&period;co&sol;post&sol;255164&sol;pfizer-backed-dao-launches-community-funded-biotech-firm<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">California Management Review&comma; &&num;8220&semi;Can Decentralized Science Be the Next Frontier of Scientific Research&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;cmr&period;berkeley&period;edu&sol;2025&sol;11&sol;can-decentralized-science-be-the-next-frontier-of-scientific-research&sol;">https&colon;&sol;&sol;cmr&period;berkeley&period;edu&sol;2025&sol;11&sol;can-decentralized-science-be-the-next-frontier-of-scientific-research&sol;<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">KuCoin Blog&comma; &&num;8220&semi;AE DeSci&comma; AI or Meme&colon; where crypto capital flows in mid-2026&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;www&period;kucoin&period;com&sol;ru&sol;blog&sol;ae-desci-ai-or-meme-where-crypto-captial-flows-in-mid-2026">https&colon;&sol;&sol;www&period;kucoin&period;com&sol;ru&sol;blog&sol;ae-desci-ai-or-meme-where-crypto-captial-flows-in-mid-2026<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">Cointelegraph&comma; &&num;8220&semi;Binance Labs invests in BIO Protocol&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;cointelegraph&period;com&sol;news&sol;binance-labs-invests-in-bio-protocol">https&colon;&sol;&sol;cointelegraph&period;com&sol;news&sol;binance-labs-invests-in-bio-protocol<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">KuCoin Research&comma; &&num;8220&semi;BIO Protocol &lpar;BIO&rpar;&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;kucoin&period;com&sol;research&sol;project-reports&sol;bio-protocol-bio">https&colon;&sol;&sol;kucoin&period;com&sol;research&sol;project-reports&sol;bio-protocol-bio<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">Molecule&comma; &&num;8220&semi;Molecule Wrapped&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;moleculeto&period;substack&period;com&sol;p&sol;molecule-wrapped">https&colon;&sol;&sol;moleculeto&period;substack&period;com&sol;p&sol;molecule-wrapped<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">The Block&comma; &&num;8220&semi;Scientists can earn crypto as Brian Armstrong startup raises &dollar;5 million&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;www&period;theblock&period;co&sol;amp&sol;post&sol;234960&sol;scientists-can-earn-crypto-as-brian-armstrong-startup-raises-5-million">https&colon;&sol;&sol;www&period;theblock&period;co&sol;amp&sol;post&sol;234960&sol;scientists-can-earn-crypto-as-brian-armstrong-startup-raises-5-million<&sol;a><&sol;p>&NewLine;<p dir&equals;"ltr">AACR&comma; &&num;8220&semi;Cancer Policy Monitor&colon; April 14&comma; 2026&&num;8221&semi;&colon; <a href&equals;"https&colon;&sol;&sol;www&period;aacr&period;org&sol;professionals&sol;policy-and-advocacy&sol;aacr-cancer-policy-monitor&sol;cancer-policy-monitor-april-14-2026&sol;">https&colon;&sol;&sol;www&period;aacr&period;org&sol;professionals&sol;policy-and-advocacy&sol;aacr-cancer-policy-monitor&sol;cancer-policy-monitor-april-14-2026&sol;<&sol;a><&sol;p>&NewLine;

Exit mobile version